Teva | octreotide acetate for injestable suspension for gluteal intramuscular use

A woman in a lab coat examines a shelf filled with various pill bottles in a laboratory setting.

Teva's Commitment to Generics

We are a leading provider of FDA-approved generic medicines in the U.S. and worldwide.

Here at Teva, we are committed to providing high-quality generic medicines to millions of patients around the world. It is our passion to produce generic medicines at costs that can help make them available to those who need them.

Facts about Teva's generics

  • We hold our generic medicines to high standards, like brand-name medicines, and meet strict FDA standards for purity and quality.
  • Our generic medicines work the same way in your body as brand-name medicines.
  • Our generic medicines contain the same active ingredients as brand-name medicines.
  • Teva generic manufacturing facilities meet the same FDA standards as brand-name facilities.

Teva leads the way in generics

  • Over 120 years of experience
  • Inspected facilities
  • FDA-approved generic medicines

Register for alerts when new Teva generics launch.

Register Today

Get to know Teva

Learn how Teva became a leader in generics.

Find Out More

Important Safety Information

What is the most important information I should know about octreotide acetate for injectable suspension?

Treatment with octreotide acetate for injectable suspension may affect gallbladder function, with reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Tell your doctor if you experience signs or symptoms of gallstones or any of their complications.

Patients with carcinoid tumors and VIP-secreting tumors should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms. 

Patients with acromegaly should adhere to their return visit schedule to help assure steady control of GH and IGF-1 levels.

What should I tell my doctor before taking octreotide acetate for injectable suspension?

Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

What are the possible side effects of octreotide acetate for injectable suspension?

In acromegalic patients, the most common side effects of octreotide acetate for injectable suspension include gallstones, diarrhea, abdominal pain, gas, flu-like symptoms, constipation, headache, low red blood cells, injection-site pain, gallstones, high blood pressure, dizziness and fatigue.

In carcinoid tumor and VIP-secreting tumor patients, the most common side effects of octreotide acetate for injectable suspension include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

These are not all of the possible side effects of octreotide acetate for injectable suspension. Call your doctor for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

What is octreotide acetate for injectable suspension?

Octreotide acetate for injectable suspension is a prescription medication used in patients in whom initial treatment with octreotide acetate injection has been shown to be effective and tolerated for:

  • Long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy, is not an option to reduce GH and IGF-1 levels to normal.
  • Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
  • Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors.

In patients with carcinoid tumors and VIP-secreting tumors, the effect of octreotide acetate injection and octreotide acetate for injectable suspension on tumor size, rate of growth and development of metastases, has not been determined.

Please see the full Prescribing Information.